Filana Therapeutics, Inc.

Filana Therapeutics, Inc. is a clinical-stage biotechnology company that develops drugs for neurodegenerative diseases. Its lead therapeutic candidate is simufilam, a small molecule drug in a Phase 3 clinical trial for Alzheimer's disease. Its investigational diagnostic candidate is SavaDx, an early-stage program focused on detecting Alzheimer's disease from a small blood sample. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. It was incorporated in 1998 and is based in Austin, Texas.